4.3 Review

Long-term maintenance treatment of psoriasis: the role of calcipotriol/betamethasone dipropionate aerosol foam in clinical practice

Journal

JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 33, Issue 5, Pages 2425-2432

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/09546634.2021.1998310

Keywords

Psoriasis; proactive management; long-term therapy; Cal; BD; adherence

Categories

Funding

  1. Leo Pharma

Ask authors/readers for more resources

Most patients with psoriasis have mild-to-moderate disease and can be treated with topical therapy as first-line treatment. A fixed-dose combination of betamethasone dipropionate and vitamin D analogue foam has been approved as the first-line topical treatment for psoriasis in the USA and EU. This position paper provides a critical discussion on the long-term management of psoriasis with this foam, including its biological rationale, evidence, and application in different disease severities and treatment regimens.
Most patients with psoriasis present with localized mild-to-moderate disease. In this case, the application of topical treatments in the first-line setting is recommended in most cases. Among different topical options, the fixed-dose combination of betamethasone dipropionate (BD) and vitamin D analogue (Cal) aerosol foam (Enstilar (R), Leo Pharma) is approved as first-line topical therapy for the treatment of psoriasis in USA and the EU, due to its high efficacy and its favorable administration scheme. The PSO-LONG was the first trial to report on the long-term efficacy and safety of the Cal/DB foam treatment for the proactive management of psoriasis and now, the indications of Cal/BD foam included its use in the psoriasis maintenance treatment. However, the precise role of this treatment and the potential therapeutic schemes in the long-term management of psoriasis need further clarification. This Position Paper, authored by a group of Italian Expert Dermatologists, critically discusses the long-term management of psoriasis with Cal/BD foam in clinical practice. In particular, the biological rationale in the proactive treatment with Cal/BD foam and current evidence regarding this therapeutic approach are presented, along with its application also in patients with moderate-to-severe disease, difficult-to-treat lesions, or within combination regimens. In addition, strategies to improve adherence to long-term treatment of psoriasis are discussed,

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available